Autoimmunity BioSolutions (ABS), a biotechnology firm, has successfully closed a $1 million seed extension, elevating its total seed funding to $3.1 million. The financing, anchored by lead investor Eos BioInnovation, is earmarked for advancing the company's innovative immuno-corrective therapy platform. This capital injection will support crucial preclinical development and help the company reach key clinical milestones for its autoimmune disease treatments.
Investor Confidence and Strategic Funding
The funding round saw continued participation from existing backers including EOS BioInnovation, Independent Capital, and Elmstead Partners. NewTech Investment Holdings also joined as a new family office investor, anchoring the $1 million extension. This broad support underscores strong investor conviction in the company's differentiated scientific approach and its long-term potential to transform patient outcomes.
Eugene Williams, CEO of Autoimmunity BioSolutions, expressed gratitude for the sustained investor support and their shared vision for the platform. He stated the capital will be purposefully deployed to complete vital animal model studies and patient bio-sample analyses. These steps are critical for advancing the company's lead program in Rheumatoid Arthritis and building on existing scientific momentum.
A Genetically Targeted Therapeutic Approach
ABS is pioneering a therapy aimed at a fundamental driver of autoimmune disease: elevated levels of soluble IL7 receptor (sIL7R). Scientific evidence has repeatedly linked high sIL7R concentrations to more severe disease outcomes and accelerated progression. The company's platform seeks to normalize these levels, offering a novel corrective strategy for patients who are inadequately served by current options.
The company's research focuses on a highly prevalent single nucleotide polymorphism (SNP) estimated to be present in approximately half the population. This genetic variant is responsible for a two-to-threefold increase in circulating sIL7R. Patients with this SNP often experience a reduced response to standard-of-care therapies across multiple autoimmune conditions, including rheumatoid arthritis and lupus nephritis.
Differentiating from Standard Autoimmune Treatments
Unlike current treatments that broadly suppress the immune system, ABS's approach is immuno-corrective and genetically guided. It specifically targets a defined subpopulation of patients marked by the high-sIL7R genetic variant. This personalized strategy aims to correct an underlying biological imbalance rather than just managing symptoms through general immunosuppression.
The company's platform holds significant promise for enhancing treatment efficacy in patients who respond poorly to existing therapies. By targeting elevated sIL7R, the therapy could be applied across numerous autoimmune diseases, including rheumatoid arthritis, lupus nephritis, and type 1 diabetes. This approach could fundamentally change the standard of care for a large refractory patient population.
This $1 million seed extension provides Autoimmunity BioSolutions with the necessary resources to advance its groundbreaking research toward the clinic. The funding will accelerate the development of a personalized therapy designed to transform outcomes for millions of autoimmune patients. With strong investor backing, the company is well-positioned to reach its next set of critical development and clinical milestones.